Virtual Issues

Refine your results

Clear all filters
Status
Tags

Biomarkers

Last updated:
20 January 2017
Biomarkers have an enormously important role in the definition of translational medicine and serve as the common language of translational sciences. The BEST (Biomarkers, EndpointS, and other Tools) Resource, authored by the FDA-NIH Biomarker Working Group, defines a biomarker as "a defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions." Biomarkers serve as the “glue” that adheres many of the component translational disciplines together, and are undergoing a renaissance of increased interest. The uptick in interest in the field of biomarkers is evident in this evolving, state-of-the-art compilation of CTS articles.

Early Clinical Trials

Last updated:
20 January 2017
One of the most dynamic and impactful aspects of translational medicine is early clinical research studies. These clinical studies often establish early proof of concept, including critical components of proof of biology, such as human genetic data and proof of safety. Early clinical trials can also offer reasonable margins to clinical dose, proof of mechanism (particularly target enlargement), and proof of activity, comprised of clinically relevant endpoints or disease-related PD/response biomarkers. The intent of this compilation of CTS articles is to showcase current, evolving, and impactful early clinical studies.

Oncology

Last updated:
20 January 2017
Clinical and translational science is foundational to oncology. Diverse oncology topics, including immune-oncology, precision medicine, early clinical results, and the development of innovative biomarkers, depend on the tenets and practice of translational medicine. The aim of this virtual issue of CTS is to publich cutting edge translational medicine in oncology drug discovery, development, and clinical usage.